-Advertisement-
-Advertisement-
Internal Medicine
Tirzepatide outperforms insulin lispro in treating type 2 diabetes
In a Phase 3b clinical trial involving 1428 adults with type 2 diabetes already on basal insulin, tirzepatide, administered as a once-weekly subcutaneous injection, demonstrated significant advantages over prandial thrice-daily insulin lispro. Tirzepatide resulted in a substantial reduction in HbA1c levels, greater weight loss, and a higher percentage of participants...
Read More-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement-

Stay Connected! Join Our Newsletter
Contact
Grandin Library Building
Six Leigh Street
Clinton, New Jersey 08809
+908-505-8899
[email protected]
© 2023 Med Journal 360™ is a trademark of International Healthcare Media, LLC. All rights Reserved